IKT vs PRLD
IKT: A pre-revenue biotech company developing IKT-001, a novel therapeutic targeting pulmonary arterial hypertension, currently in Phase 3 clinical trials with no approved products or operating revenue. PRLD: An early-stage biopharma company developing novel small-molecule drug candidates targeting protein-driven disease mechanisms.
Side-by-side fundamentals
| Metric | IKT | PRLD | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.17 | $3.92 | |
| Market cap as of 2026-07-23 | $287M | $313M | |
| Net margin as of 2026-07-23 | -5981.3% | -278.5% | PRLD higher |
| Operating margin as of 2026-07-23 | -6253.1% | -310.7% | PRLD higher |
| ROE as of 2026-07-23 | -57.1% | -74.6% | IKT higher |
| ROA as of 2026-07-23 | -52.8% | -39.3% | PRLD higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +41.0% | |
| Beta as of 2026-07-23 | 0.97 | 0.94 | |
| 1-year return as of 2026-07-22 close | +18.6% | +379.8% | PRLD higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.